

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

483 M

Board of Directors

Mr Iain Ross

Chairman
Non-Executive Director

Mr Bryce Carmine

Deputy Chairman
Non-Executive Director

Mr Steven Coffey

Non-Executive Director

Dr James Garner

Chief Executive Officer
Managing Director

ASX RELEASE

04 July 2017

NOVOGEN MODIFIES NASDAQ ADR PROGRAM

Sydney, 04 July 2017 – Australian oncology-focused biotechnology company Novogen Limited (ASX: NRT; NASDAQ: NVGN) announces a ratio change on the American Depositary Receipt (“ADR”) program from 25 Ordinary shares representing 1 Depository Share (“DS”) (25: 1 ratio) to a new ratio of 100 Ordinary shares representing 1 DS (100: 1 ratio). The change will take effect on 14 July 2017.

An ADR represents a bundle of Ordinary shares which can be traded on NASDAQ. Currently around 37% of the Company’s Ordinary shares are held in this way.

The change in the ADR ratio will have no effect on the number of outstanding Ordinary shares the Company has on issue or the listing of its Ordinary shares on the ASX.

In making the announcement Novogen’s Chairman, Iain Ross stated, “the ratio change and resulting increase in the market price for our ADR shares as listed on NASDAQ will bring our ADR shares back into compliance with NASDAQ’s US\$1.00 minimum bid price requirement. We believe that continued listing on both the ASX and NASDAQ provides important liquidity and compliance on two major exchanges for our shareholders and for Novogen.”

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of development candidates, diversified across several distinct technologies, with the potential to yield first-in-class and best-in-class agents in a range of oncology indications.

The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. A second clinical program, TRXE-002-01 (Cantrixil) commenced a phase I clinical trial in ovarian cancer in December 2016. In addition, the company has several preclinical programs in active development, the largest of which is substantially funded by a CRC-P grant from the Australian Federal Government.

For more information, please visit: www.novogen.com